Deep Dive: Deep Dive Into Cholangiocarcinoma

On this episode of Deep Dive, you’ll hear from Jesper B. Andersen, associate professor and group leader at the University of Copenhagen and the Biotech Research and Innovation Center at the Department of Health. Andersen discusses how recent years brought exciting FDA approvals in the cholangiocarcinoma space, though the majority of patients are still receiving older standard-of-care options because their specific disease subtype may not be eligible for new targeted therapies, highlighting a pressing need for more research in this area.